Skip to main content

Research Repository

Advanced Search

All Outputs (40)

Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study (2021)
Journal Article
Wang, M., Ramchandren, R., Chen, R., Karlin, L., Chong, G., Jurczak, W., …Tam, C. S. (2021). Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study. Journal of Hematology and Oncology, 14, Article 179. https://doi.org/10.1186/s13045-021-01188-x

Ibrutinib plus venetoclax, given with an ibrutinib lead-in, has shown encouraging clinical activity in early phase studies in mantle cell lymphoma (MCL). The ongoing phase 3 SYMPATICO study evaluates the safety and efficacy of concurrently administer... Read More about Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study.

Population‐based cohort study of the efficacy of brentuximab vedotin in relapsed systemic anaplastic large‐cell lymphoma using Public Health England data (2021)
Journal Article
Halligan, S. J., Grainge, M. J., Martinez-Calle, N., Fox, C. P., & Bishton, M. J. (2022). Population‐based cohort study of the efficacy of brentuximab vedotin in relapsed systemic anaplastic large‐cell lymphoma using Public Health England data. British Journal of Haematology, 196(4), 932-938. https://doi.org/10.1111/bjh.17896

Systemic anaplastic large cell lymphoma (sALCL) is a rare T-cell lymphoma associated with poor prognosis after relapse. The immuno-conjugate Brentuximab Vedotin (BV) first became available for relapsed sALCL in England in 2013, following the results... Read More about Population‐based cohort study of the efficacy of brentuximab vedotin in relapsed systemic anaplastic large‐cell lymphoma using Public Health England data.

A validation study of the identification of haemophagocytic lymphohistiocytosis in England using population-based health data (2021)
Journal Article
Bishton, M. J., Stilwell, P., Card, T. R., Lanyon, P., Ban, L., Elliss-Brookes, L., …Bythell, M. (2021). A validation study of the identification of haemophagocytic lymphohistiocytosis in England using population-based health data. British Journal of Haematology, 194(6), 1039-1044. https://doi.org/10.1111/bjh.17768

We assessed the validity of coded healthcare data to identify cases of haemophagocytic lymphohistiocytosis (HLH). Hospital Episode Statistics (HES) identified 127 cases within five hospital Trusts 2013–2018 using ICD-10 codes D76.1, D76.2 and D76.3.... Read More about A validation study of the identification of haemophagocytic lymphohistiocytosis in England using population-based health data.

Improved survival outcomes despite older age at diagnosis: an era‐by‐era analysis of patients with primary central nervous system lymphoma treated at a single referral centre in the United Kingdom (2021)
Journal Article
Kaji, F. A., Martinez‐Calle, N., Bishton, M. J., Figueroa, R., Adlington, J., O’Donoghue, M., …Fox, C. P. (2021). Improved survival outcomes despite older age at diagnosis: an era‐by‐era analysis of patients with primary central nervous system lymphoma treated at a single referral centre in the United Kingdom. British Journal of Haematology, 195(4), 561-570. https://doi.org/10.1111/bjh.17747

Observational studies with long-term follow-up of patients with primary central nervous system lymphoma (PCNSL) are scarce. Patient data over a period of four decades were retrospectively analysed from databases at Not-tingham University Hospitals Tr... Read More about Improved survival outcomes despite older age at diagnosis: an era‐by‐era analysis of patients with primary central nervous system lymphoma treated at a single referral centre in the United Kingdom.

Systemic ALCL Treated in Routine Clinical Practice: Outcomes Following First-Line Chemotherapy from a Multicentre Cohort (2021)
Journal Article
Martinez-Calle, N., Kirkwood, A. A., Lamb, M., Smith, A., Khwaja, J., Manos, K., …Fox, C. P. (2021). Systemic ALCL Treated in Routine Clinical Practice: Outcomes Following First-Line Chemotherapy from a Multicentre Cohort. Advances in Therapy, 38(7), 3789-3802. https://doi.org/10.1007/s12325-021-01764-0

Introduction: Brentuximab vedotin (BV)-CHP is the new standard regimen for first-line treatment of systemic anaplastic large cell lymphoma (sALCL). We undertook a retrospective analysis of consecutive patients diagnosed with sALCL, treated in routine... Read More about Systemic ALCL Treated in Routine Clinical Practice: Outcomes Following First-Line Chemotherapy from a Multicentre Cohort.

Treatment patterns and outcomes of unfit and elderly patients with Mantle cell lymphoma unfit for standard immunochemotherapy: A UK and Ireland analysis (2021)
Journal Article
Rampotas, A., Wilson, M. R., Lomas, O., Denny, N., Leary, H., Ferguson, G., …Eyre, T. A. (2021). Treatment patterns and outcomes of unfit and elderly patients with Mantle cell lymphoma unfit for standard immunochemotherapy: A UK and Ireland analysis. British Journal of Haematology, 194(2), 365-377. https://doi.org/10.1111/bjh.17513

Mantle cell lymphoma (MCL) presenting in elderly, unfit patients represents a clinical challenge. Front-line ‘attenuated’ or low-intensity immunochemotherapy is often employed, although outcomes are relatively unexplored. We report outcomes of attenu... Read More about Treatment patterns and outcomes of unfit and elderly patients with Mantle cell lymphoma unfit for standard immunochemotherapy: A UK and Ireland analysis.

Infection-related morbidity and mortality among older patients with DLBCL treated with full- or attenuated-dose R-CHOP (2021)
Journal Article
Eyre, T. A., Wilson, W., Kirkwood, A. A., Wolf, J., Hildyard, C., Plaschkes, H., …Hatton, C. S. R. (2021). Infection-related morbidity and mortality among older patients with DLBCL treated with full- or attenuated-dose R-CHOP. Blood Advances, 5(8), 2229-2236. https://doi.org/10.1182/bloodadvances.2021004286

Infection-related morbidity and mortality are increased in older patients with diffuse large B-cell lymphoma (DLBCL) compared with population-matched controls. Key predictive factors for infection-related hospitalization during treatment with rituxim... Read More about Infection-related morbidity and mortality among older patients with DLBCL treated with full- or attenuated-dose R-CHOP.

The diagnostic and therapeutic challenges of Grade 3B follicular lymphoma (2021)
Journal Article
Barraclough, A., Bishton, M., Cheah, C. Y., Villa, D., & Hawkes, E. A. (2021). The diagnostic and therapeutic challenges of Grade 3B follicular lymphoma. British Journal of Haematology, 195(1), 15-24. https://doi.org/10.1111/bjh.17404

Grade 3B follicular lymphoma (G3B FL) is rare, accounting for only 5–10% of FLs. Not only has it been routinely excluded from clinical trials, but data published on diagnosis, outcomes, choice of therapies and role of imaging are conflicting. With th... Read More about The diagnostic and therapeutic challenges of Grade 3B follicular lymphoma.

Scedosporium apiospermum brain abscesses in a patient receiving ibrutinib and venetoclax (2020)
Journal Article
Figueroa, R., Martinez‐Calle, N., Prescott, K., & Bishton, M. (2020). Scedosporium apiospermum brain abscesses in a patient receiving ibrutinib and venetoclax. eJHaem, 1(2), 418-419. https://doi.org/10.1002/jha2.121

An 80-year-old male, with relapsed mantle cell lymphoma was treated on a trial with the combination of the bruton tyrosine kinase (BTK) inhibitor, ibrutinib, and BH3-mimetic, venetoclax, and achieved complete remission by both Computerized Tomography... Read More about Scedosporium apiospermum brain abscesses in a patient receiving ibrutinib and venetoclax.

Extended follow‐up of CD4 + T cell recovery kinetics in a large cohort of patients with B‐cell lymphoproliferative disease treated with rituximab‐bendamustine (2020)
Journal Article
Gaiolla, R., Hartley, S., Beech, A., Knight, H., Smith, D., Bishton, M., …Martinez-Calle, N. (2021). Extended follow‐up of CD4 + T cell recovery kinetics in a large cohort of patients with B‐cell lymphoproliferative disease treated with rituximab‐bendamustine. Hematological Oncology, 39(1), 137-140. https://doi.org/10.1002/hon.2797

The UK NCRI study of chlorambucil, mitoxantrone and dexamethasone (CMD) versus fludarabine, mitoxantrone and dexamethasone (FMD) for untreated advanced stage follicular lymphoma: molecular response strongly predicts prolonged overall survival (2020)
Journal Article
Bishton, M. J., Rule, S., Wilson, W., Turner, D., Patmore, R., Clifton‐Hadley, L., …Haynes, A. (2020). The UK NCRI study of chlorambucil, mitoxantrone and dexamethasone (CMD) versus fludarabine, mitoxantrone and dexamethasone (FMD) for untreated advanced stage follicular lymphoma: molecular response strongly predicts prolonged overall survival. British Journal of Haematology, 190(4), 545-554. https://doi.org/10.1111/bjh.16555

We present a long-term follow-up of the UK chlorambucil, mitoxantrone and dexamethasone (CMD) versus fludarabine, mitoxantrone and dexamethasone (FMD) for untreated advanced, symptomatic follicular lymphoma (FL). This trial was the first to prospecti... Read More about The UK NCRI study of chlorambucil, mitoxantrone and dexamethasone (CMD) versus fludarabine, mitoxantrone and dexamethasone (FMD) for untreated advanced stage follicular lymphoma: molecular response strongly predicts prolonged overall survival.

Outcome in patients with diffuse large B-cell lymphoma who relapse after autologous stem cell transplantation and receive active therapy. A retrospective analysis of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (EBMT) (2019)
Journal Article
E, G.-B., A, B., D, B., M, T., T, M., H, F., …A, S. (2020). Outcome in patients with diffuse large B-cell lymphoma who relapse after autologous stem cell transplantation and receive active therapy. A retrospective analysis of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplantation, 55(2), 393-399. https://doi.org/10.1038/s41409-019-0650-x

Autologous hematopoietic stem cell transplantation (auto-HSCT) is the standard of care for patients with diffuse large B-cell lymphoma (DLBCL) who relapse/progress after first line chemoimmunotherapy. Long-term outcome of those who relapse after tran... Read More about Outcome in patients with diffuse large B-cell lymphoma who relapse after autologous stem cell transplantation and receive active therapy. A retrospective analysis of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (EBMT).

Stand-alone intrathecal central nervous system (CNS) prophylaxis provide unclear benefit in reducing CNS relapse risk in elderly DLBCL patients treated with R-CHOP and is associated increased infection-related toxicity (2019)
Journal Article
Eyre, T. A., Kirkwood, A. A., Wolf, J., Hildyard, C., Mercer, C., Plaschkes, H., …Hatton, C. S. R. (2019). Stand-alone intrathecal central nervous system (CNS) prophylaxis provide unclear benefit in reducing CNS relapse risk in elderly DLBCL patients treated with R-CHOP and is associated increased infection-related toxicity. British Journal of Haematology, 187(2), 185-194. https://doi.org/10.1111/bjh.16070

Central nervous system (CNS) relapse following R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone) occurs in 2–5% of patents with diffuse large B-cell lymphoma (DLBCL). Many patients aged ≥70 years are unsuitable for high-dos... Read More about Stand-alone intrathecal central nervous system (CNS) prophylaxis provide unclear benefit in reducing CNS relapse risk in elderly DLBCL patients treated with R-CHOP and is associated increased infection-related toxicity.

A multicenter retrospective comparison of induction chemoimmunotherapy regimens on outcomes in transplant-eligible patients with previously untreated mantle cell lymphoma (2019)
Journal Article
Ng, Z. Y., Bishton, M., Ritchie, D., Campbell, R., Gilbertson, M., Hill, K., …Cheah, C. Y. (2019). A multicenter retrospective comparison of induction chemoimmunotherapy regimens on outcomes in transplant-eligible patients with previously untreated mantle cell lymphoma. Hematological Oncology, 37(3), 253-260. https://doi.org/10.1002/hon.2618

Mantle cell lymphoma (MCL) is an uncommon and typically aggressive form of lymphoma. Although often initially chemosensitive, relapse is common. Several induction and conditioning regimens are used in transplant-eligible patients, and the optimal app... Read More about A multicenter retrospective comparison of induction chemoimmunotherapy regimens on outcomes in transplant-eligible patients with previously untreated mantle cell lymphoma.

Male gender is an independent predictor for worse survival and relapse in a large, consecutive cohort of elderly DLBCL patients treated with R-CHOP (2019)
Journal Article
Eyre, T. A., Martinez‐Calle, N., Hildyard, C., Eyre, D. W., Plaschkes, H., Griffith, J., …Hatton, C. S. R. (2019). Male gender is an independent predictor for worse survival and relapse in a large, consecutive cohort of elderly DLBCL patients treated with R-CHOP. British Journal of Haematology, 186(4), https://doi.org/10.1111/bjh.15927

Refractoriness to rituximab-based therapy and elevated serum B2-microglobulin predict for inferior survival in marginal zone lymphoma (2019)
Journal Article
Sorigue, M., Bishton, M., Domingo-Domenech, E., McMillan, A., Prusila, R., García, O., …Sancho, J. (2019). Refractoriness to rituximab-based therapy and elevated serum B2-microglobulin predict for inferior survival in marginal zone lymphoma. Leukemia & Lymphoma, 60(10), 2524-2531. https://doi.org/10.1080/10428194.2019.1594212

Short responses to immunochemotherapy predict for an inferior OS in follicular lymphoma. We set out to determine whether this is also the case in marginal zone lymphoma. A group of 139 marginal zone lymphoma (MZL) patients treated with front-line imm... Read More about Refractoriness to rituximab-based therapy and elevated serum B2-microglobulin predict for inferior survival in marginal zone lymphoma.

COO and MYC/BCL2 status do not predict outcome among patients with stage I/II DLBCL: a retrospective multicenter study (2019)
Journal Article
Barraclough, A., Alzahrani, M., Ettrup, M. S., Bishton, M., van Vliet, C., Farinha, P., …Cheah, C. Y. (2019). COO and MYC/BCL2 status do not predict outcome among patients with stage I/II DLBCL: a retrospective multicenter study. Blood Advances, 3(13), 2013-2021. https://doi.org/10.1182/bloodadvances.2019000251

In advanced-stage diffuse large B-cell lymphoma (DLBCL), the presence of an activated B-cell phenotype or a non–germinal center (GCB) phenotype, coexpression of MYC and BCL2 by immunohistochemistry, and the cooccurrence of MYC and BCL2 or BCL6 rearra... Read More about COO and MYC/BCL2 status do not predict outcome among patients with stage I/II DLBCL: a retrospective multicenter study.

Kinetics of T-cell subset reconstitution following treatment with bendamustine and rituximab for low-grade lymphoproliferative disease: a population-based analysis (2018)
Journal Article
Martínez-Calle, N., Hartley, S., Ahearne, M., Kasenda, B., Beech, A., Knight, H., …Fox, C. P. (2019). Kinetics of T-cell subset reconstitution following treatment with bendamustine and rituximab for low-grade lymphoproliferative disease: a population-based analysis. British Journal of Haematology, 184(6), 957-968. https://doi.org/10.1111/bjh.15722

Delayed lymphocyte and T-cell immune reconstitution following bendamustine-rituximab (BR) for indolent non-Hodgkin lymphoma (iNHL) has been described, but no information is available for chronic lymphocytic leukaemia (CLL). We present a population-ba... Read More about Kinetics of T-cell subset reconstitution following treatment with bendamustine and rituximab for low-grade lymphoproliferative disease: a population-based analysis.

A single-arm, phase II study of the anti-BLYS monoclonal antibody belimumab in symptomatic waldenstrom macroglobulinemia (2013)
Journal Article
Bishton, M., Spencer, A., Dickinson, M., & Ritchie, D. (2013). A single-arm, phase II study of the anti-BLYS monoclonal antibody belimumab in symptomatic waldenstrom macroglobulinemia. Clinical Lymphoma, Myeloma and Leukemia, 13(5), 575-578. https://doi.org/10.1016/j.clml.2013.04.006

Background: The B-lymphocyte stimulator (BLYS) protein is known to regulate immunoglobulin in normal B cells, and be overexpressed in B-cell malignancies, including Waldenstrom macroglobulinemia (WM). Patients and Methods: This trial evaluated the sa... Read More about A single-arm, phase II study of the anti-BLYS monoclonal antibody belimumab in symptomatic waldenstrom macroglobulinemia.